Company Profile
10x Genomics Stock Price, News & Catalysts
- Ticker:
- TXG
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
88.76 USD (-1.77%)
Close
Last updated: October 1, 2026
3.9B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, TXG closed down 1.77% at $88.76. No new same-company headline was identified in the current news window.
Company overview
Single-Cell and Spatial Biology Company
10x Genomics develops instruments, consumables, software, and analysis tools that allow researchers to measure biological systems at single-cell and spatial resolution. Its platforms are used across academic research, translational medicine, biopharma discovery, and emerging diagnostic applications.
Chromium Single-Cell Platform
The Chromium platform partitions cells and biological molecules for high-throughput analysis of gene expression, immune repertoires, chromatin accessibility, and multiomic features. Instrument placements support recurring sales of proprietary chips, reagents, and workflow consumables.
Visium Spatial Profiling
Visium products measure gene expression while preserving tissue location, allowing researchers to connect molecular signals with histology and tissue architecture. The platform supports discovery across oncology, neuroscience, immunology, developmental biology, and pathology research.
Xenium In Situ Analysis
Xenium performs targeted, high-plex RNA analysis directly within tissue sections at subcellular resolution. It complements Visium by enabling researchers to study selected gene panels with detailed spatial localization and cell-level morphology.
Next-Generation Platforms and Software
Atera is designed to expand the scale and flexibility of spatial biology, while the acquisition of Proteintech Genomics adds antibody-based protein measurement capabilities. 10x Genomics is also investing in software and computational tools that convert large single-cell and spatial datasets into interpretable biological conclusions.
Future catalysts
- Global commercial shipments of the Atera spatial biology platform in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of 10x Genomics (TXG)?
10x Genomics (TXG) most recently closed at 88.76 USD, a -1.77% move versus the previous session.
What is the market cap of 10x Genomics (TXG)?
10x Genomics currently has a market capitalization of 3.9B USD on BioPharmSignal.
What does 10x Genomics do?
Single-Cell and Spatial Biology Company 10x Genomics develops instruments, consumables, software, and analysis tools that allow researchers to measure biological systems at single-cell and spatial resolution. Its platforms are used across academic research, translational medicine, biopharma discovery, and emerging diagnostic applications. Chromium...
On which exchange is TXG stock listed?
10x Genomics (TXG) is associated with NASDAQ, United States, Biopharma.
What is Single-Cell?
Single-Cell and Spatial Biology Company 10x Genomics develops instruments, consumables, software, and analysis tools that allow researchers to measure biological systems at single-cell and spatial resolution.
Which conditions is 10x Genomics targeting with Single-Cell?
10x Genomics is associated with oncology, immunology, neuroscience based on its company overview and current catalyst commentary.
How does 10x Genomics describe recent progress with Single-Cell?
Global commercial shipments of the Atera spatial biology platform in the second half of 2026.
What is Spatial?
Single-Cell and Spatial Biology Company 10x Genomics develops instruments, consumables, software, and analysis tools that allow researchers to measure biological systems at single-cell and spatial resolution.